Retrospective cohort confirms higher mortality and healthcare resource use in sickle cell patients with recurrent complications, suggesting need for novel therapies.
Patients with SCD with recurrent VOCs had substantially higher rates of complications, mortality, and HCRU than controls, further highlighting the need for novel therapies to reduce VOCs and the associated burden.
No takes yet. Share an insight, caveat, or question.
Lilly et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: